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Abstract
In their article on the use of barbiturates for the treatment of
intracranial hypertension after traumatic brain injury, Perez-Barcena
and colleagues conclude that thiopental was more effective than
pentobarbital in decreasing intracranial pressure. Here we discuss
the limitations of this study and review areas of controversy
surrounding barbiturate use in neurocritical care.
Raised intracranial pressure (ICP) after traumatic brain injury
(TBI) is common and associated with increased risk for death
and disability. Despite decades of animal and human
research, successful prevention and treatment of this deadly
complication largely eludes the medical community. Because
of the considerable heterogeneity and severity of the disease,
well designed, prospective, randomized studies in neuro-
trauma are rare. All academic attempts to generate reliable
trial data are noteworthy.
In this context, we enthusiastically applaud Pérez-Bárcena and
colleagues [1] for their thoughtful and ambitious research. The
study evaluates the use of two barbiturates, pentobarbital and
thiopental, in the treatment of refractory intracranial hyper-
tension after TBI. Forty-four patients were randomly assigned
to receive pentobarbital or thiopental after first-level measures
had failed to control ICP. In the pentobarbital and thiopental
groups, ICP was controlled in 18% and 50% of patients,
respectively, without any statistically significant difference
between groups in the rate of infectious complications or
hemodynamic compromise. Glasgow Outcome Scale (GOS)
scores at 6 months revealed a poor neurologic outcome
(death, vegetative state, and severe disability) in 17 and 12
patients in the pentobarbital and thiopental groups,
respectively. No statistical analysis of GOS scores was
reported, but the study was not powered to detect a
difference in outcome.
The study has several limitations, which the authors
themselves note. Specifically, cranial computed tomography
revealed bilateral brain swelling in significantly more patients
in the pentobarbital group, and more patients in the thiopental
group had evacuated lesions or no swelling at all. In addition,
the doses of barbiturate were not equivalent between groups.
To compensate for this, the authors attempted to ensure
equivalent potency by titrating the dose to electrographic
burst suppression (EBS) or flat pattern. However, the number
of patients in each group that reached EBS was not reported;
therefore, it is unclear whether bioequivalent doses were
actually achieved between groups. Previous research has
shown that the serum concentration at which EBS is reached
varies between patients, and serum and cerebrospinal fluid
levels correlate poorly with EBS [2]. Therefore, EBS is not
necessarily an accurate surrogate for barbiturate dose. Given
that thiopental is more lipophilic than pentobarbital and was
infused at a higher initial maintenance rate, it is possible that
the thiopental group maintained a higher cerebral
concentration of barbiturate [3].
Despite these potential confounders, the relevance of this
trial cannot be overstated. In the current age of multimodality
monitoring, individualized treatment paradigms, and combi-
nation therapy, these data have important implications and
bring to the forefront a number of questions.
What is the appropriate goal of barbiturate therapy - ICP
control, EBS, neuroprotection, or a combination of these?
Experimental models of ischemia demonstrate that anesthetic
doses of barbiturates provide no additional attenuation of
brain free fatty acid release than subanesthetic doses [4]. In
models of focal infarction, animals that were anesthetized
with pentobarbital dosed to preserve an active electro-
encephalogram had equivalent reductions in infarct volume
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as those anesthetized to EBS [5]. Barbiturates lessen the
release of S-100B, excitatory neurotoxins, and amino acid
markers of energy failure, but it has not been proven that EBS
is a requirement for these neurochemical changes [6,7].
These data cast doubt on the argument that patients benefit
maximally from barbiturate protocols that include EBS as a
therapeutic target, especially given the frequent adverse
effects of hypotension and immune dysfunction.
Nevertheless, several studies convincingly demonstrate that
barbiturates can treat elevated ICP, particularly in patients
who are refractory to other management strategies [8,9]. If
barbiturates can lower ICP and provide neuroprotection even
without EBS, then why has an association with good
outcomes not been realized in clinical trials [10]? Perhaps by
the time barbiturates are employed for refractory ICP - often
several days after the trauma - the opportunity for the drugs
to prevent secondary injury has passed. Alternatively, it is
plausible that only specific pathophysiologic and cerebral
hemodynamic profiles will respond to barbiturate treatment.
Pérez-Bárcena and coworkers [1] reported that the associa-
tion of focal lesions with ICP control was 3.6 times higher
than that for diffuse lesions. Improved pressure reactivity
indices and cerebral tissue oxygen tension in response to
barbiturates, even in the presence of continued elevations in
ICP, predict a favorable outcome [8]. These findings raise the
possibility that in select patients barbiturates have the ability
to prevent localized ischemia, reverse dysautoregulation, and
improve cerebral oxygenation. Finally, barbiturates may
indeed provide an outcome benefit, but were not superior to
other drugs - including opiates, mannitol, hypertonic saline,
and benzodiazepines - that were used in controls.
Despite insufficient evidence that either pentobarbital or
thiopental improves outcomes after TBI, or that one drug is
better than the other, the future for barbiturates still looks
bright. Early combination therapy of barbiturates with hypo-
thermia or progesterone, in concert with multimodality
invasive neuromonitoring, holds promise in the treatment of
this devastating condition [11-14].
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